Medical/Pharmaceuticals
Genevoyager Unveils Gene Therapy CDMO Facility in Milestone Move
PHILADELPHIA, Dec. 20, 2023 /PRNewswire/ -- Genevoyager (Wuhan) Co., Ltd. (Genevoyager), a leading provider of one-stop CRO/CDMO services for gene therapy products, proudly announces the official opening of its Contract Development and Manufacturing Organization (CDMO) facility. This significant ...
2023-12-20 23:10
1639
HanAll Biopharma, Daewoong Pharmaceutical and NurrOn Pharmaceuticals to Showcase Ongoing Parkinson's Disease Program at the 7th Annual Sachs Associates Neuroscience Innovation Forum
ROCKVILLE, Md., Dec. 20, 2023 /PRNewswire/ -- HanAll Biopharma (KRX: 009420.KS), Daewoong Pharmaceutical (KRX: 069620.KS), and NurrOn Pharmaceuticals announced their participation in the 7th Annual Sachs Associates Neuroscience Innovation Forum. The event is scheduled to take place onJanuary 7th...
2023-12-20 20:00
1662
InxMed Enters License Agreement with Escugen to Develop Next-Generation ADCs
NANJING, China, Dec. 19, 2023 /PRNewswire/ -- InxMed, a clinical-stage biotechnology company dedicates on developing innovative therapies against drug resistance, and Escugen, a clinical-stage antibody–drug conjugate (ADC) company, today announced that InxMed licensed EZWi-Fit® linker-payload pl...
2023-12-20 09:00
1670
Standigm named as a Tech Innovator in Generative AI in Drug Discovery use case
SEOUL, South Korea, Dec. 19, 2023 /PRNewswire/ -- Standigm
2023-12-19 22:00
1566
New Drug Application of Mabwell's 8MW0511 for Injection Accepted by NMPA
SHANGHAI, Dec. 19, 2023 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced that the new drug application of its recombinant (yeast-secreted) human serum albumin-human granulocyte colony-stimulating factor (I) fusion protein for injec...
2023-12-19 20:00
1462
Tianjin's Youthful Energy Sparks Citywide Revival
TIANJIN, China, Dec. 19, 2023 /PRNewswire/ -- A report from China Daily: Tianjin, a city in North China, is undergoing a dynamic transformation driven by its vibrant young people. China Daily Potside Chats hosts, Nathan and Stephanie, recently explored the city's cutting-edge developments led by ...
2023-12-19 15:44
1718
Biorithm Secures $3.5 Million in Series A Funding to Advance Maternal Care Worldwide
New funds to fortify US market entry and growth strategy, as well as advance breakthrough research CAMBRIDGE, Mass., Dec. 18, 2023 /PRNewswire/ -- Biorithm, a global women's health medtech, has closed$3.5 million in Series A funding, co-led by Adaptive Capital Partners and SEEDS Capital. With a ...
2023-12-18 22:00
1497
Neuren Phase 2 trial shows significant improvements in Phelan-McDermid syndrome
Highlights: * Significant improvement was assessed by both clinicians and caregivers across multiple efficacy measures * Improvements were consistently seen across clinically important aspects of Phelan-McDermid syndrome, including communication, behaviour, cognition/learning and socialis...
2023-12-18 19:00
1261
NUS researchers develop an innovative and flexible method to study immune cell capabilities
This simple and efficient method can directly identify and sort immune cells involved in cell-mediated cytotoxicity SINGAPORE, Dec. 17, 2023 /PRNewswire/ -- Our body's immune system is a complex network of organs, cells, and proteins that work in synchrony to protect our bodies against infection...
2023-12-18 14:47
1509
GC Biopharma Announces US FDA Approval for ALYGLO™ (Immune Globulin Intravenous, Human-stwk) 10% Liquid for Adults with Primary Humoral Immunodeficiency (PI)
YOGIN, South Korea, Dec. 17, 2023 /PRNewswire/ -- GC Biopharma Corp (006280.KS) today announces that the US Food and Drug Administration (FDA) has approved ALYGLO (immune globulin intravenous, human-stwk) 10% Liquid, formerly referred to as "GC5107," for the treatment of adult patients aged 17...
2023-12-18 09:49
1610
GeneQuantum and BioMap establish a strategic collaboration to jointly develop a series of next-generation ADC therapeutics
SUZHOU, China, Dec. 17, 2023 /PRNewswire/ -- Recently, GeneQuantum Healthcare (GQ), a global leader in ADC new drug development focused on innovative bioconjugation technologies, and BioMap, a global leader in life science AI Foundation protein-centric Large Language Models, announced that the...
2023-12-18 09:43
1441
First Patient Dosed in Clinical Trial of YOLT-201 for the Treatment of Hereditary ATTR-CM
SHANGHAI, Dec. 17, 2023 /PRNewswire/ -- YolTech Therapeutics today announced that the first patient has been dosed with YOLT-201, the company's firstin vivo genome editing candidate being developed as a single dose, potentially curative therapy for hereditary transthyretin amyloidosis with cardio...
2023-12-17 23:15
1632
Caliway Closes Oversubscribed Capital Raise and Secures Over $100M to Advance CBL-514 Pivotal Phase 3 Study in Subcutaneous Fat Reduction
TAIPEI, Dec. 16, 2023 /PRNewswire/ -- Caliway Biopharmaceuticals (Caliway) announced that it has closed an oversubscribed capital raise, securing over$100M by issuing 8 million new shares. The new funding will enable Caliway to advance the clinical development of its lead pipeline CBL-514, a sma...
2023-12-16 15:47
2038
SeekIn and OncoInv Collaborate to Expand the Global Accessibility of Multiple Cancer Detection Tests and Bridge Global Disparities in Cancer Care
SeekIn to Grant Oncolnv the Rights to Represent SeekIn's Comprehensive Range of Cancer Detection Tests in Twelve Countries to Provide Individuals with Accessible and Affordable Cancer Detection Tests SHENZHEN, China, Dec. 15, 2023 /PRNewswire/ -- SeekIn Inc, a leader in blood-based cancer early ...
2023-12-15 21:00
1575
Akeso Published Results from CD47 Antibody Ligufalimab in Combination with Azacitidine for Newly Diagnosed Higher-Risk Myelodysplastic Syndrome and Treatment-naïve Acute Myeloid Leukemia at ASH 2023
HONG KONG, Dec. 15, 2023 /PRNewswire/ -- Akeso published two phase Ib clinical results of its innovative CD47 monoclonal antibody ligufalimab (AK117) in combination with azacitidine in patients with newly diagnosed higher-risk myelodysplastic syndrome (HR-MDS) and treatment-naïve acute myeloid le...
2023-12-15 21:00
1678
Live from ASH 2023 | Oral Report Featuring Encouraging Data of Olverembatinib Combined with Reduced-Intensity Chemotherapy in Patients with Ph+ ALL Presented at the ASH Annual Meeting
SUZHOU, China and ROCKVILLE, Md., Dec. 14, 2023 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today thatProf. Xiaoyuan Gong of the Institute of Hemato...
2023-12-15 11:14
1884
Nona Biosciences Enters into a Global License Agreement with Pfizer for HBM9033, an MSLN-Targeted Antibody-Drug Conjugate (ADC)
* Nona Biosciences will receive a total of up to $53 Million in upfront and near-term payments, with the potential for milestones of up to$1.05 billion plus royalties. * Pfizer partnership expands Nona's global network of collaborations, reinforcing its commitment to providing cutting-edge te...
2023-12-15 07:30
1739
Lunit to Acquire Volpara: Scheme Implementation Agreement Signed
- Lunit's strategic global leap: to acquire all of Volpara shares at AUD 1.15 per share, envisioning completion by Q2 2024 SEOUL. South Korea, Dec. 14, 2023 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, today announced ...
2023-12-14 22:05
1544
China Jo-Jo Drugstores Granted A Second Extension to Meet Nasdaq Minimum Bid Price Requirement
HANGZHOU, China, Dec. 14, 2023 /PRNewswire/ -- China Jo-Jo Drugstores, Inc. (NASDAQ: CJJD) (the "Company"), a leading online and offline retailer and wholesale distributor of pharmaceutical and other healthcare products and healthcare provider inChina, today announced that on December 13, 2023, t...
2023-12-14 21:30
3560
Titans Gather, Future Embarks: The GenScript Biotech Global Forum coinciding with the 2024 J.P. Morgan Healthcare Conference in San Francisco to Convene 20+ KOLs, Exploring Disruptive Transformations and Infinite Opportunities in GCT
Keynote speaker Peter Marks to Deliver Address Free Early Bird Registration Closing Soon NANJING, China, Dec. 14, 2023 /PRNewswire/ -- Technological advancements continuously empower the life sciences. Gene and cell therapy (GCT), as breakthrough treatments, are turning the once-unreachable dre...
2023-12-14 20:34
2461
Week's Top Stories
Most Reposted
Rocket Travel by Agoda Shares Revealing New Report and Showcases Solution to Transform Hotel Distribution
[Picked up by 313 media titles]
2024-11-21 10:30Rockwell Automation and Microsoft Deliver on a Shared Vision to Accelerate Industrial Transformation
[Picked up by 308 media titles]
2024-11-20 13:29Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
[Picked up by 301 media titles]
2024-11-20 16:30
Travel loyalty programs to focus on offering personalized and flexible customer experiences in 2025
[Picked up by 298 media titles]
2024-11-19 10:42Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
[Picked up by 284 media titles]
2024-11-20 09:00
Most Read
Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
2024-11-20 16:30
5608
